Researchers at the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences in Novosibirsk have developed a novel antiviral agent derived from interferon lambda, a protein that plays a key role in the body’s antiviral defense mechanisms. The obtained results provide a foundation for further clinical trials and may contribute to the development of a new drug based on domestic pharmaceutical innovations to combat viral infections, including coronavirus.
The study was conducted at the Research Institute of Clinical and Experimental Lymphology, a branch of the Instutute of Cytology and Genetics, the institute’s press service told TASS. For the first time, scientists have demonstrated in virological experiments that an oral, interferon-based drug exhibits specific antiviral activity against SARS-CoV-2, rendering it neutralizing.
It has also been found that the oral form increases the substance’s bioavailability in tissues. This suggests that the drug could be a promising new addition to the antiviral therapy of SARS-CoV-2.
Interferons are high molecular weight proteins that primarily exhibit antiviral activity. One of the most effective is IFN-λ (interferon lambda). Recent studies have shown that patients with COVID-19 have reduced interferon production, meaning they need external administration to treat the infection. However, when ingested, interferons often lose their activity. To address this issue, scientists in Novosibirsk have developed an oral medication that can be conveniently administered.
Earlier it became known that the Russian pharmaceutical company Binnopharm Group and the Research Institute of Clinical and Experimental Lymphology, a branch of the Instutute of Cytology and Genetics of the Siberian Branch of the RAS, will work together on a new drug for the treatment of diseases of the gastrointestinal tract, which is expected to be ready for commercial production in the late 2027.